Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brintellix in major depressive disorder
NCT01153009Phase 3Completed
- Sponsor
- Takeda
- Start
- Jun 2010
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD), sponsored by Takeda. Started Jun 2010; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01153009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01153009.